Horizon 2020 e la SC 1: Health, well being and demographic change Programma di lavoro 2014-2015 e novita' all' interno del bando Alessandra Martini Commissione Europea DG Ricerca e Innovazione Open Info Day Horizon 2020 'Health, demographic change and wellbeing'
39
Embed
Open Info Day Horizon 2020 'Health, demographic change and ...grantoffice.ioveneto.it/images/Documenti/Presentazione Bandi - Euro… · Open Info Day Horizon 2020 'Health, demographic
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Horizon 2020 e la SC 1: Health, well being and demographic change
Programma di lavoro 2014-2015 e novita' all' interno del bando
Alessandra MartiniCommissione EuropeaDG Ricerca e Innovazione
Open Info DayHorizon 2020 'Health, demographic
change and wellbeing'
Proposed funding(million EUR, 2014-2020)*
All funding figures in this presentation are subject to the pending Multiannual Financial Framework Regulation by the EP and the Council
Health, demographic change and wellbeing (DG R&I and DG CONNECT)
7 472
Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the Bioeconomy
3 851
Secure, clean and efficient energy * 5 931
Smart, green and integrated transport 6 339
Climate action, environment, resource efficiency and raw materials
3 081
Inclusive, innovative and reflective societies 1 310
Secure societies 1 695
Science with and for society 462
Spreading excellence and widening participation 816
•Both in vivo and in vitro potential biomarkers are eligible.
•Preference will be given to the validation of disease-related biomarkers (i.e. diagnostic, susceptibility/risk, monitoring and prognostic biomarkers), but drug biomarkers are not excluded.
•Validation of the performance of new diagnostic devices (either in combination with the biomarker validation, or against existing standards).
Phase 1 and Phase 2 27
TOTAL Budget: 2014: 66.10 mill EUR 2015: 45 mill EUR
Background
•Global market for diagnostics is in expansion ($80 billion in 2013 worldwide), in particular for biomarkers (compound annual growth rate of 18.5%).
•90% of the companies in the sector are SMEs.
•R&D bottleneck (around 25000 biomarkers identified each year that are in most cases not validated) and market failure with insufficient investments, as clinical validation is risky and valorisation of the diagnostic is poor (IVD is only 5% of medical product expenses).
Topic of the SME instrument
28
PHC 12 – 2014 and 2015: Clinical validation of biomarkers and/or diagnostic medical devices
2. Impact […] extent to which project outputs contribute to: The expected impacts listed in the work programme under the relevant topic;
Enhancing innovation capacity and integration of new knowledge;
Strengthening the competitiveness and growth of companies by developing innovations meeting the needs of European and global markets;
Effectiveness of the proposed measures to communicate the project, disseminate and/or exploit the project results, and appropriate management of IPR.
3. Quality and efficiency of implementation Coherence and effectiveness of the work plan, including appropriateness of the
allocation of tasks and resources;
Competences, experience and complementarity of the individual participants, as well as of the consortium as a whole;
Appropriateness of the management structures and procedures, including risk management
Scoring/weights/thresholds
As in FP7 each criterion scored out of 5; thresholds will be applied for each criterion and the total score, different depending on the call and action
Unlike FP7, for Innovation Actions and SME instrument…
impact criterion weighted by factor of 1.5 Impact considered first when scores equal